LABORATORIOS FARMACEUTICOS ROVI SA

ISIN: ES0157261019 WKN: - Asset Class: Stock



Company Profile

Laboratorios Farmaceúticos Rovi SA engages in the research, development, manufacture, and marketing of small molecule and specialty biologic drugs. It operates through the following business segments: Manufacturing, Marketing, and Other. The Manufacturing segment obtains its income from service contracts that relate to the finalization of the pharmaceutical product production process for external entities and the manufacture of products to be subsequently marketed by other group companies. The Marketing segment purchases and sells pharmaceutical products. The Other segment includes other services, research, and development activities that are not significant for the group. The company was founded on December 21, 1946 and is headquartered in Madrid, Spain.

Financial figures, Fiscal year: from 01.01. to 31.12.

	20	23	20	ว ว	20	21
Financial figures		Liabilities and equity		Liabilities and equity		Liabilities and equity
Current assets	511,124,000		624,949,000		510,108,000	
Common stock capital		3,241,000		3,241,000		3,364,000
Fixed assets	288,760,000		253,754,000		222,568,000	
Equity capital of a company		543,494,000		521,379,000		470,976,000
Cash and cash equivalents	25,322,000		124,945,000		99,035,000	
Accrued liabilities		0		0		0
Other assets	-		-		-	
Current liabilities		200,461,000		293,928,000		190,406,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		54,570,000		61,622,000		68,963,000
Different income		-		-		-
Other liabilities		1,431,000		1,545,000		1,460,000
Total assets	799,884,000	799,884,000	878,703,000	878,703,000	732,676,000	732,676,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	2,111	1,993	1,751
Equity ratio	68.46%	59.49%	64.28%
Debt-equity ratio	46.07%	68.09%	55.57%

Others			
	2023	2022	2021
Tax Expense Rate	22.72%	22.62%	16.20%

LABORATORIOS FARMACEUTICOS ROVI SA

ISIN: ES0157261019 WKN: - Asset Class: Stock

Income statement

	2023	2022	2021
Turnover	829,509,000	817,698,000	648,677,000
Net income	170,335,000	199,669,000	153,077,000
EBIT	221,474,000	258,611,000	183,283,000
Operating income before taxes	220,533,000	257,768,000	182,446,000
Cash Flow	114,348,000	237,317,000	149,221,000
Net interest income	-941,000	-843,000	-837,000
Research and development expenses	24,923,000	23,869,000	27,445,000
Income taxes	50,109,000	58,302,000	29,551,000
Result from investments in subsidaries, associates and other	-125,000	199,000	182,000
Revenues per employee	392,946	410,285	370,461

Board of Directors

Iván López-Belmonte Encina	Member of Supervisory Board
Javier López-Belmonte Encina	Member of Supervisory Board
Marcos Peña Pinto	Member of Supervisory Board
Marina del Corral Téllez	Member of Supervisory Board
María Fátima Báñez García	Member of Supervisory Board
Teresa Santamaría	Member of Supervisory Board

Members of Management Board

Juan López-Belmonte Encina	Chairman of Managing Board
Aránzazu Lozano Pirrongelli	Member of Executive Committee
Beatriz Avila Alcalde	Member of Executive Committee
Fernando Martínez Garijo	Member of Executive Committee
Francisco Javier Ángulo García	Member of Executive Committee
Gabriel Núñez Fernández	Member of Executive Committee
Ibón Gutierro Adúriz	Member of Executive Committee
M. Rosario Perucha Perez	Member of Executive Committee
Marta Campos Martínez	Member of Executive Committee
Mercedes Benitez del Castillo Sanchez	Member of Executive Committee
Miguel Angel Castillo Román	Member of Executive Committee